Trial Profile
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs INCB 59872 (Primary) ; Azacitidine; Nivolumab; Tretinoin
- Indications Acute myeloid leukaemia; Cancer; Ewing's sarcoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Incyte Corporation
- 29 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 30 Apr 2022 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 23 Apr 2021 Planned End Date changed from 14 Dec 2021 to 31 May 2022.